Nemdatine (Memantine Hydrochloride)

Nemdatine is an NMDA receptor antagonist used in the management of Alzheimer’s disease and related cognitive decline.

• Moderate to severe Alzheimer’s disease: improves cognition and functional abilities in affected patients.
• Cognitive impairment due to Alzheimer’s disease: helps maintain daily living skills.
• Functional decline in Alzheimer’s disease: may slow progression of daily activity loss.

• Memantine hydrochloride acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel, it reduces excessive calcium influx caused by glutamate over‑activation, thereby decreasing excitotoxic neuronal injury and supporting neuronal function in Alzheimer’s disease.

Adverse reactions to memantine are reported across a range of frequencies.

Common Side Effects

• Dizziness: transient light‑headedness reported by some patients.
• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Confusion: occasional mental clouding.
• Fatigue: feeling unusually tired.
• Hypertension: elevated blood pressure in some cases.

Serious or Rare Side Effects

• Seizures: rare but potentially life‑threatening.
• Cardiac arrhythmias: abnormal heart rhythms observed infrequently.
• Severe allergic reactions: rash, swelling, or anaphylaxis.
• Stevens‑Johnson syndrome: rare skin disorder.
• Hepatic dysfunction: abnormal liver enzymes.
• Psychosis: rare emergence of hallucinations or delusions.

Memantine should be used with attention to patient‑specific factors and storage requirements.

• Renal impairment: assess kidney function and adjust therapy if necessary.
• History of seizures: monitor closely for increased seizure activity.
• Concurrent NMDA agonists: avoid co‑administration due to opposing mechanisms.
• Pregnancy: safety not established; use only if clearly needed.
• Elderly patients: observe for confusion or worsening cognition.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with several medicines, requiring clinical awareness.

Major Interactions (Avoid)

• Amantadine: combined use can increase CNS adverse effects.
• Ketamine: additive NMDA antagonism may lead to excessive inhibition.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may reduce therapeutic benefit.
• Diuretics: can raise memantine plasma concentrations.
• CNS depressants (e.g., benzodiazepines): may enhance sedation and dizziness.